阿帕替尼联合卡培他滨治疗晚期食管癌效果观察  

Efficacy observation of apatinib combined with capecitabine in the treatment of advanced esophageal cancer

作　　者：叶宏勋[1] 尹小祥[1] 赵莺[1] 古亮[1] 孙红娟[1] Ye Hongxun;Yin Xiaoxiang;Zhao Ying;Gu Liang;Sun Hongjuan(Department of Radiotherapy,Taixing People's Hospital of Jiangsu Province,Taixing 225400,China)

机构地区：[1]江苏省泰兴市人民医院放疗科,225400

出　　处：《肿瘤研究与临床》2020年第3期170-173,共4页Cancer Research and Clinic

摘　　要：目的观察阿帕替尼联合卡培他滨对晚期食管癌的疗效。方法选取2017年6月至2018年2月于江苏省泰兴市人民医院接受治疗的101例晚期食管癌患者,按随机数字表法分为对照组(50例)和观察组(51例),对照组给予卡培他滨联合放疗,观察组在对照组的基础上服用阿帕替尼。比较两组患者的疗效、不良反应及无进展生存(PFS)时间。结果观察组总有效率为90.2%(46/51),高于对照组的72.0%(36/50),差异有统计学意义(χ^2=5.473,P=0.019)。两组患者白细胞减少、中性粒细胞减少、血小板减少、贫血、蛋白尿、高血压发生情况比较,差异均无统计学意义(均P>0.05)。观察组中位PFS时间为18.49个月(95%CI 15.35~25.03个月),长于对照组的13.33个月(95%CI 10.36~18.24个月),差异有统计学意义(χ^2=5.995,P<0.01)。结论阿帕替尼联合卡培他滨治疗晚期食管癌效果确切,无明显不良反应发生,PFS时间延长。Objective To observe the efficacy of apatinib combined with capecitabine in the treatment of advanced esophageal cancer.Methods A total of 101 patients with advanced esophageal cancer in Taixing People's Hospital of Jiangsu Province from June 2017 to February 2018 were enrolled,and all the patients were divided into the control group(50 cases)and the observation group(51 cases)according to the random number table.The control group was treated with capecitabine combined with radiotherapy,and the observation group was treated with apatinib on the basis of the control group.The therapeutic effects,adverse reactions and progression-free survival(PFS)time of the two groups were compared.Results The overall response rate in the observation group was higher than that in the control group[90.2%(46/51)vs.72.0%(36/50)],and the difference was statistically significant(χ^2=5.473,P=0.019).There were no significant differences in leukopenia,neutropenia,thrombocytopenia,anemia,proteinuria and hypertension between the two groups(all P>0.05).The median PFS time in the observation group was 18.49 months(95%CI 15.35-25.03 months),and that in the control group was 13.33 months(95%CI 10.36-18.24 months),and the difference between the two groups was statistically significant(χ^2=5.995,P<0.01).Conclusions The therapeutic effect of apatinib combined with capecitabine in the treatment of advanced esophageal cancer is accurate.No obvious adverse reaction occurs,and the PFS time is prolonged.

关 键 词：食管肿瘤 药物疗法 联合 阿帕替尼 卡培他滨 

分 类 号：R735[医药卫生—肿瘤]